$25.00
0.090.36%
At Close: -
$25.60
0.62.40%
After Hours: 4:58 PM EDT
15 minutes delayed
BridgeBio Pharma
BBIONASDAQ
BridgeBio Pharma (NASDAQ:BBIO) Stock, Analyst Ratings, Price Targets, Predictions
BridgeBio Pharma Inc has a consensus price target of $40.5, established from looking at the 50 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, B of A Securities, and HC Wainwright & Co. on July 1, 2024, June 25, 2024, and June 20, 2024. With an average price target of $51.67 between Cantor Fitzgerald, B of A Securities, and HC Wainwright & Co., there's an implied 101.82% upside for BridgeBio Pharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
B of A Securities
HC Wainwright & Co.
UBS
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for BridgeBio Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/01/2024 | Buy Now | 173.44% | Cantor Fitzgerald | Josh Schimmer | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 06/25/2024 | Buy Now | 64.06% | B of A Securities | Geoff Meacham | $50 → $42 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | 67.97% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 67.97% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | 67.97% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 173.44% | Cantor Fitzgerald | Josh Schimmer | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 05/28/2024 | Buy Now | 83.59% | UBS | Eliana Merle | $51 → $47 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 67.97% | HC Wainwright & Co. | Raghuram Selvaraju | $47 → $43 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 95.31% | Evercore ISI Group | Cory Kasimov | → $50 | Initiates | → Outperform | Get Alert |
| 03/20/2024 | Buy Now | 75.78% | JP Morgan | Anupam Rama | $35 → $45 | Maintains | Overweight | Get Alert |
| 03/19/2024 | Buy Now | 173.44% | Cantor Fitzgerald | Josh Schimmer | $60 → $70 | Maintains | Overweight | Get Alert |
| 03/11/2024 | Buy Now | 134.37% | Cantor Fitzgerald | Josh Schimmer | $50 → $60 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 107.03% | Mizuho | Salim Syed | $60 → $53 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 83.59% | HC Wainwright & Co. | Raghuram Selvaraju | → $47 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 79.69% | Citigroup | David Lebowitz | $42 → $46 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 44.53% | BMO Capital | Kostas Biliouris | → $37 | Initiates | → Market Perform | Get Alert |
| 01/29/2024 | Buy Now | 83.59% | HC Wainwright & Co. | Raghuram Selvaraju | $22 → $47 | Maintains | Buy | Get Alert |
| 01/22/2024 | Buy Now | 95.31% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 64.06% | Citigroup | David Lebowitz | → $42 | Initiates | → Buy | Get Alert |
| 10/24/2023 | Buy Now | 95.31% | Cantor Fitzgerald | Josh Schimmer | → $50 | Initiates | → Overweight | Get Alert |
| 08/28/2023 | Buy Now | 134.37% | Mizuho | Salim Syed | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | Buy Now | 48.44% | JP Morgan | Anupam Rama | $42 → $38 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 134.37% | Mizuho | Salim Syed | $50 → $60 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 95.31% | Goldman Sachs | Paul Choi | $29 → $50 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 79.69% | Raymond James | Dane Leone | $29 → $46 | Maintains | Outperform | Get Alert |
| 07/18/2023 | Buy Now | 28.91% | Jefferies | Eun Yang | $24 → $33 | Downgrade | Buy → Hold | Get Alert |
| 05/08/2023 | Buy Now | 13.28% | Mizuho | Salim Syed | $23 → $29 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 56.25% | Evercore ISI Group | Josh Schimmer | → $40 | Initiates | → Outperform | Get Alert |
| 04/13/2023 | Buy Now | 5.47% | SVB Securities | Mani Foroohar | $25 → $27 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | -10.16% | JP Morgan | Anupam Rama | $18 → $23 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 9.37% | Goldman Sachs | Paul Choi | $20 → $28 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 13.28% | Raymond James | Dane Leone | $17 → $29 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren | — | Initiates | → Outperform | Get Alert |
| 01/23/2023 | Buy Now | -25.78% | SVB Leerink | Mani Foroohar | $23 → $19 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | -25.78% | JP Morgan | Anupam Rama | $20 → $19 | Maintains | Overweight | Get Alert |
| 08/24/2022 | Buy Now | -10.16% | Mizuho | Salim Syed | $25 → $23 | Maintains | Buy | Get Alert |
| 07/26/2022 | Buy Now | 17.19% | SVB Leerink | Mani Foroohar | $27 → $30 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | -25.78% | Goldman Sachs | Paul Choi | $24 → $19 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 5.47% | SVB Leerink | Mani Foroohar | $26 → $27 | Maintains | Outperform | Get Alert |
| 03/16/2022 | Buy Now | -14.06% | HC Wainwright & Co. | Raghuram Selvaraju | $24 → $22 | Maintains | Buy | Get Alert |
| 03/11/2022 | Buy Now | -29.69% | JP Morgan | Anupam Rama | $21 → $18 | Maintains | Overweight | Get Alert |
| 03/09/2022 | Buy Now | 1.56% | SVB Leerink | Mani Foroohar | $25 → $26 | Maintains | Outperform | Get Alert |
| 03/04/2022 | Buy Now | -2.34% | SVB Leerink | Mani Foroohar | $24 → $25 | Maintains | Outperform | Get Alert |
| 12/28/2021 | Buy Now | -6.25% | HC Wainwright & Co. | Raghuram Selvaraju | $88 → $24 | Maintains | Buy | Get Alert |
| 12/28/2021 | Buy Now | -6.25% | SVB Leerink | Mani Foroohar | $66 → $24 | Maintains | Outperform | Get Alert |
| 11/19/2021 | Buy Now | 157.81% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
| 10/25/2021 | Buy Now | 243.75% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 10/04/2021 | Buy Now | 165.62% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
| 09/10/2021 | Buy Now | 192.97% | B of A Securities | Geoff Meacham | — | Upgrade | Neutral → Buy | Get Alert |
| 08/06/2021 | Buy Now | 157.81% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for BridgeBio Pharma (BBIO) stock?
The latest price target for BridgeBio Pharma (NASDAQ:BBIO) was reported by Cantor Fitzgerald on July 1, 2024. The analyst firm set a price target for $70.00 expecting BBIO to rise to within 12 months (a possible 173.44% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
The latest analyst rating for BridgeBio Pharma (NASDAQ:BBIO) was provided by Cantor Fitzgerald, and BridgeBio Pharma reiterated their overweight rating.
When was the last upgrade for BridgeBio Pharma (BBIO)?
The last upgrade for BridgeBio Pharma Inc happened on September 10, 2021 when B of A Securities raised their price target to $75. B of A Securities previously had a neutral for BridgeBio Pharma Inc.
When was the last downgrade for BridgeBio Pharma (BBIO)?
The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $70.00 to $70.00. The current price BridgeBio Pharma (BBIO) is trading at is $25.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.